Longevium, a Dubai-based healthcare network, has secured $7 million in its first funding round to establish a new Longevity AI Research Laboratory. The state-of-the-art facility, located in Dubai Science Park, is slated to open in the final quarter of 2026. This initiative aims to pioneer technologies that predict health risks, measure biological aging, and significantly extend healthy human lifespans.
A New Frontier in Preventive Healthcare
The new laboratory will function as a dedicated research and development hub, bridging the gap between biomedical research and clinical practice. It supports Dubai's strategic goal to become a global leader in longevity medicine and aligns with the vision of the Dubai Longevity Authority. The facility will translate vast clinical data into powerful AI-driven tools for preventive healthcare, strengthening the emirate's innovation ecosystem.
Pioneering AI-Driven Innovations
A key focus of the lab will be the development of patient-specific digital twins using groundbreaking Yamanaka factors. This technology will enable physicians to simulate the effects of medications and personalized treatment protocols on a virtual model. Consequently, this allows for the optimization of therapies and the proactive assessment of individual disease risks before any clinical intervention.
The research will also advance robotic diagnostics and next-generation wearable technology for continuous health monitoring. Innovations include swallowable capsules for gastrointestinal imaging and AI-powered skin scanners for early melanoma detection. Furthermore, smart contact lenses that analyze tear fluid will provide real-time health data, transforming how personal wellness is managed.
Longevium is expanding its research into regenerative medicine, tissue engineering, and the therapeutic potential of noble gases. The program will investigate advanced cell technologies to restore organ function and explore treatments for age-related conditions. Xenon gas, in particular, shows promise for organ protection and managing stress-related disorders, with other gases also under investigation.
Leveraging an Established Clinical Network
This ambitious project is built upon Longevium's established network of three clinics across Dubai, which has served over 30,000 patients. This existing infrastructure, supported by a team of nearly 100 physicians, provides a crucial environment for longitudinal data collection. It serves as a real-world setting for developing and validating new approaches to preventive and longevity medicine.
Dr. Ksenia Butova, Founder and CEO of Longevium, stated that the mission is to make advanced longevity innovations widely accessible. The company is actively recruiting leading scientists and inviting collaboration with research institutions, investors, and technology partners. This collaborative approach is central to achieving the vision of a future where healthier, longer lives are possible for more people.
The $7 million investment marks a significant milestone for Longevium and the broader healthcare landscape in the UAE. The new Longevity AI Research Lab is poised to accelerate the development of transformative health technologies, from digital twins to regenerative therapies. This initiative solidifies Dubai's position as an emerging global hub for longevity research and next-generation preventive medicine.